Suppr超能文献

纤维性骨发育不良性骨化性纤维发育不良和其他形式的异位骨化中的炎症。

Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.

机构信息

Division of Endocrinology and Metabolism, University of California, 513 Parnassus Ave., HSE901, San Francisco, CA, 94143-0794, USA.

Department of Medicine, The Institute for Human Genetics, University of California, CA, San Francisco, USA.

出版信息

Curr Osteoporos Rep. 2019 Dec;17(6):387-394. doi: 10.1007/s11914-019-00541-x.

Abstract

PURPOSE OF REVIEW

Heterotopic ossification (HO) is associated with inflammation. The goal of this review is to examine recent findings on the roles of inflammation and the immune system in HO. We examine how inflammation changes in fibrodysplasia ossificans progressiva, in traumatic HO, and in other clinical conditions of HO. We also discuss how inflammation may be a target for treating HO.

RECENT FINDINGS

Both genetic and acquired forms of HO show similarities in their inflammatory cell types and signaling pathways. These include macrophages, mast cells, and adaptive immune cells, along with hypoxia signaling pathways, mesenchymal stem cell differentiation signaling pathways, vascular signaling pathways, and inflammatory cytokines. Because there are common inflammatory mediators across various types of HO, these mediators may serve as common targets for blocking HO. Future research may focus on identifying new inflammatory targets and testing combinatorial therapies based on these results.

摘要

目的综述

异位骨化(HO)与炎症有关。本综述的目的是探讨炎症和免疫系统在 HO 中的作用的最新发现。我们研究了纤维性骨发育不良进展过程中、创伤性 HO 中和 HO 其他临床情况下炎症的变化。我们还讨论了炎症如何成为治疗 HO 的靶点。

最近的发现

遗传性和获得性 HO 均显示出其炎症细胞类型和信号通路的相似性。这些包括巨噬细胞、肥大细胞和适应性免疫细胞,以及缺氧信号通路、间充质干细胞分化信号通路、血管信号通路和炎症细胞因子。由于各种类型的 HO 中存在共同的炎症介质,这些介质可能成为阻断 HO 的共同靶点。未来的研究可能集中在识别新的炎症靶点和根据这些结果测试组合疗法上。

相似文献

1
Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Curr Osteoporos Rep. 2019 Dec;17(6):387-394. doi: 10.1007/s11914-019-00541-x.
2
Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Biomolecules. 2024 Mar 16;14(3):357. doi: 10.3390/biom14030357.
3
Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
Med Hypotheses. 2019 Oct;131:109313. doi: 10.1016/j.mehy.2019.109313. Epub 2019 Jul 20.
4
Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Br J Clin Pharmacol. 2019 Jun;85(6):1180-1187. doi: 10.1111/bcp.13823. Epub 2019 Jan 6.

引用本文的文献

3
Heterotopic ossification: Current developments and emerging potential therapies.
Chin Med J (Engl). 2025 Feb 20;138(4):389-404. doi: 10.1097/CM9.0000000000003244. Epub 2025 Jan 17.
4
Mast cell activation by NGF drives the formation of trauma-induced heterotopic ossification.
JCI Insight. 2024 Nov 26;10(1):e179759. doi: 10.1172/jci.insight.179759.
5
Increased TSPO, COX-1, and COX-2 Uptake in Bone Marrow Within a Falx Cerebri Ossification.
Clin Nucl Med. 2024 Nov 1;49(11):e604-e605. doi: 10.1097/RLU.0000000000005491. Epub 2024 Oct 3.
7
Estrogen Deficiency Exacerbates Traumatic Heterotopic Ossification in Mice.
J Inflamm Res. 2024 Aug 23;17:5587-5598. doi: 10.2147/JIR.S477382. eCollection 2024.
8
Fibrodysplasia ossificans progressiva: Two case reports.
Radiol Case Rep. 2024 May 3;19(8):2973-2977. doi: 10.1016/j.radcr.2024.04.019. eCollection 2024 Aug.
9
Genetic regulation of injury-induced heterotopic ossification in adult zebrafish.
Dis Model Mech. 2024 May 1;17(5). doi: 10.1242/dmm.050724. Epub 2024 May 31.
10
Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.
Rheumatology (Oxford). 2024 Sep 1;63(9):2597-2604. doi: 10.1093/rheumatology/keae255.

本文引用的文献

1
Heterotopic Ossification: A Comprehensive Review.
JBMR Plus. 2019 Feb 27;3(4):e10172. doi: 10.1002/jbm4.10172. eCollection 2019 Apr.
2
Heterotopic ossification following suboccipital craniectomy decompression surgery for Chiari malformation type I: case report.
J Neurosurg Pediatr. 2019 Mar 29;23(6):704-707. doi: 10.3171/2019.1.PEDS18680. Print 2019 Jun 1.
3
Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury.
Front Immunol. 2019 Mar 7;10:377. doi: 10.3389/fimmu.2019.00377. eCollection 2019.
4
Failure of Indomethacin and Radiation to Prevent Blast-induced Heterotopic Ossification in a Sprague-Dawley Rat Model.
Clin Orthop Relat Res. 2019 Mar;477(3):644-654. doi: 10.1097/CORR.0000000000000594.
5
NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.
JCI Insight. 2018 Nov 15;3(22):122958. doi: 10.1172/jci.insight.122958.
6
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Stem Cell Reports. 2018 Nov 13;11(5):1106-1119. doi: 10.1016/j.stemcr.2018.10.007. Epub 2018 Nov 1.
8
Inhibition of overactive TGF-β attenuates progression of heterotopic ossification in mice.
Nat Commun. 2018 Feb 7;9(1):551. doi: 10.1038/s41467-018-02988-5.
9
Circulating osteogentic precursor cells in non-hereditary heterotopic ossification.
Bone. 2018 Apr;109:61-64. doi: 10.1016/j.bone.2017.12.028. Epub 2018 Jan 3.
10
Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验